-
Glucose Drug Reduces Heart Disease in People with Diabetes
14 June 2016. A drug to reduce glucose levels was shown in a clinical trial to reduce serious heart disease in people with type 2 diabetes also at high risk of heart disease. Results of the late-stage trial testing the drug liraglutide, marketed by drug-maker Novo Nordisk under the brand name Victoza, appear in yesterday’s…
-
Trial Underway Testing Drug to Reduce Chronic Cough
14 June 2016. A clinical trial testing a drug treating chronic cough — coughs continuing for 8 weeks or more — will begin recruiting participants in the U.K. to join other sites in the U.S. The U.K. sites are under the direction of National Institute for Health Research, testing a small molecule, or low molecular…
-
Consortium Aims to Upgrade Cell Manufacturing
13 June 2016. A collaboration between businesses and universities outlined a strategy to develop processes and technologies for large-scale manufacturing of human cells for therapies and diagnostics. The National Cell Manufacturing Consortium, residing at Georgia Institute of Technology, announced its technology road map for advance cell manufacturing today at a White House conference on organ…
-
FDA Approves Cholera Vaccine
13 June 2016. Food and Drug Administration approved for marketing the U.S. a vaccine to prevent cholera for travelers to regions in the world where contaminated food or water is causing the disease. Vaxchora by PaxVax Inc. in Redwood City, California is the first vaccine approved by the agency to prevent cholera. According to World…
-
Process Devised to Quickly Isolate Bacteria in Lab Samples
10 June 2016. A biomedical engineering center at Harvard University developed a process for quickly isolating staph bacteria from clinical samples for lab testing. The team led by Donald Ingber, director of the Wyss Institute for Biologically Inspired Engineering at Harvard, published its findings earlier this week in the journal PLoS One. Ingber and colleagues…
-
New Diabetic Eye Disease Drugs Shown Not Cost-Effective
10 June 2016. An evaluation of two new biologic drugs to treat diabetic macular edema, an eye disease caused by diabetes, show the drugs do not provide enough additional benefit over much less expensive treatments to justify their higher price tags. The team led by Adam Glassman of the Jaeb Center for Health Research in…
-
Clinical Center, Mobile Developer Partner on Diabetes Apps
9 June 2016. A clinical center specializing in metabolic disorders is collaborating with a designer of mobile diabetes software on research to upgrade and enhance the company’s apps. Financial terms of the agreement between Profil Institute for Clinical Research in Chula Vista, California and mySugr GmbH in Vienna, Austria were not disclosed. The company mySugr…
-
Antibody Treatment Shown to Prevent Migraine
9 June 2016. A clinical trial shows an engineered antibody in one week reduced the number of headaches in people who experienced migraines for an average of 18 years. Results of the study testing the experimental treatment appear in yesterday’s issue of the journal Neurology, published by American Academy of Neurology. Migraine is a neurological syndrome…
-
FDA Clears Insomnia Relief Device
8 June 2016. A device that helps people with insomnia get to sleep without taking drugs received clearance for marketing in the U.S. from the Food and Drug Administration. The device, developed by the company Cerêve in Pittsburgh, Pennsylvania, will require a prescription once it’s on the market in the U.S., expected in the second…
-
Kauffman Index Shows Higher Start-Up Growth in 2016
8 June 2016. An index of high-growth start-up companies shows the rate of entrepreneurial expansion in the U.S. accelerated for the third year in a row, with greatest concentration of growing enterprises found in the Washington, D.C. region. The Ewing Marion Kauffman Foundation in Kansas City, Missouri yesterday issued its annual Index of Growth Entrepreneurship…